GSK’s Bird Flu Vaccine Might Need An Outbreak To Get Full Approval
Executive Summary
The company stressed that because the government will have control of the vaccine stockpile, a partnership is necessary to evaluate the efficacy of the Q-Pan H5N1 vaccine during a pandemic.
You may also be interested in...
Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav
FDA’s Vaccines and Related Biological Products Advisory Committee recommended 8 to 5 with one abstention that Dynavax acquire more safety data pre-licensure for its hepatitis B vaccine.
Possibility Of A Pandemic Helped GSK’s Q-Pan H5N1 Flu Vaccine Get Panel Support
FDA’s Vaccines and Related Biological Products Advisory Committee said in twin 14-0 votes that immunogenicity and safety data are sufficient to support approval.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.